Rawshani Lab
Gothenburg Cardiometabolic Research Group
Open lectures
20 Aug, 1 pm (2025), Teams
Efficacy and Safety of Semaglutide: From PIONEER to CagriSema. Lecturer: Araz Rawshani
Principal investigator (PI)
Araz Rawshani, MD, PhD, Associate professor
Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg
Department of Cardiology, Sahlgrenska University Hospital
Group
Vibha Gupta (vibha.gupta@gu.se), PhD, Engineer, post doc
Adam Piasecki, (adam.piasecki@vgregion.se), MD, PhD, post doc
Linnea Gustafsson (linnea.gustafsson@vgregion.se), MD, PhD student
Daniella Isaksén (daniella.isaksen@vgregion.se), MD, PhD student
George Lappas (george.lappas@gu.se), senior statistician
Johan Widing, MD cand, Master student
Pedram Sultanian, MD, PhD, post doc
Erik Andersson, MD cand, Researcher
Lukas Hilgendorf, MD, PhD student
Alfred Hjalmarsson, MD cand, Researcher
Arman Shahmari, MD cand, Researcher
Rawshani Lab in The Swedish Medical Bulletin for Benchmarking of Swedish Medical Research
Ongoing projects
Proteomic Signatures of Diabetes Across the Obesity Spectrum
Using UK Biobank data, we investigate how type 2 diabetes shapes the circulating proteome and metabolome across varying degrees of obesity. We explore distinct biomarker patterns by adiposity and links these to genetic risk for obesity and diabetes.
Deep Learning for the Detection of Coronary Artery Stenosis, Flow-Limiting Plaques and Vulnerable Plaques
Project using 18,000 coronary CT angiographies to create fully-automated interpretation of coronary CT scans.
Vibha Gupta, Lukas Hilgendorf, Erik Andersson
Cardiometabolic Drug Discovery with Boltz‑2
Harnessing the power of Boltz‑2, a cutting-edge AI model for protein–ligand interaction and binding affinity prediction, to explore small molecules targeting diabetes and obesity. By combining structural precision with high-throughput virtual screening, we explore the discovery of next-generation therapies for cardiometabolic diseases.
Phd cand: Arman Shahmari.
Fully automated ECG interpretation of acute coronary syndromes
Phd cand: Lukas Hilgendorf, MD
MariTide (GLP1RA, anti-GIPR)
Clinical trial, currently recruiting patients at Sahlgrenska Hospital, Östra Sjukhuset. Initiated by AMGEN. Contact for more information.
Digital Cardiometabolic Graphs
We explore means of transform large, unstructured cardiometabolic databases -spanning clinical trials, omics data, imaging, and observational studies – into high-quality, annotated corpora for machine learning. By combining expert curation with scalable automation, the goal is to build a foundation for next-generation AI models that can reason across molecular, genetic, and clinical dimensions of obesity, diabetes, and cardiovascular disease.
Master thesis: Johan Widing
TrialNet - Efficient Inclusion to Randomized Clinical Trials
TrialNet 1 aims to enable fully-automated and rapid identification of patients eligible for randomized controlled trials. Expected to launch Q4 2025.
TrialNet 2 aims to leverage large language models to scan EHRs for patients eligible for ongoing clinical trials, and connect them to trial units.
GLP1-RA and Pericoronary Adipose Tissue
Postponed.
Clinical prediction models for cardiovascular care
SCARS-1
Predict 30-days survival after out-of-hospital cardiac arrest.
SCARS-2
Predict 30-days survival after in-of-hospital cardiac arrest.
SCARS-3
Predict long-term survival at discharge after OHCA.
For students
Basic clinical research methods in R and Python
A free online course teaching basic programming and methods in R and Python.
Start: www.Science.nu
By: Araz Rawshani, Aidin Rawshani
The AI in Healthcare Conference 17 Dec 2024
The conference AI In Healthcare was overbooked and a success.
